Aim: Intratumoral (IT) electroporation (EP) of plasmid IL-12 promotes systemic anti-tumor immunity and is being evaluated in Phase 2 trials. In patients ( pts) with advanced melanoma (MEL) treated with IL-12 EP, regression of non-injected lesions was seen in 4/19 pts in the Phase I study and 13/21 pts in the ongoing Phase 2 study. This study explores systemic efficacy and immune correlates in clinical samples and in a bilateral MEL model, utilizing the poorly immunogenic B16 cell line, to test the hypothesis that intratumoral IL-12 EP can enhance tumor immunogenicity. Methods: Pre-and post-treatment biopsies and blood were collected from MEL trial pts. A B16 2-tumor MEL model was developed in mice. Tumors treated with IL-12 EP were compared to untreated tumors in the same animal. mRNA was evaluated by NanoString and leukocyte populations by IHC and flow cytometry.
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